ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

{"_buckets": {"deposit": "41221f44-ad70-4f48-ab42-7ebf3ade2f69"}, "_deposit": {"id": "2003747", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "2003747"}, "status": "published"}, "_oai": {"id": "oai:nagoya.repo.nii.ac.jp:02003747", "sets": ["1662337921058"]}, "author_link": [], "control_number": "2003747", "item_1615768549627": {"attribute_name": "出版タイプ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_9_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2022-08", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "3", "bibliographicPageEnd": "553", "bibliographicPageStart": "547", "bibliographicVolumeNumber": "84", "bibliographic_titles": [{"bibliographic_title": "Nagoya Journal of Medical Science", "bibliographic_titleLang": "en"}]}]}, "item_9_description_4": {"attribute_name": "内容記述", "attribute_value_mlt": [{"subitem_description": "Although the Cockcroft-Gault equation is still used for the dose adjustment of many drugs that have been approved prior to creatinine standardization, the clinical impact of standardized creatinine in the dose adjustment of capecitabine is poorly understood. We focused on patients with borderline renal function and evaluated the tolerability and safety of capecitabine in patients who received capecitabine plus oxaliplatin (Cape-Ox). We retrospectively identified patients with resected colorectal cancer who had received adjuvant therapy with Cape-Ox regimen. Creatinine clearance (CrCL) was calculated by the Cockcroft–Gault equation with standardized creatinine measured using enzymatic methods, and adjusted CrCL was estimated by adding 0.2 (mg/dL) to the serum creatinine in the equation. We defined patients with “pseudo-normal” renal function as those who had an adjusted CrCL of ≤50 mL/min in patients with normal renal function (CrCL \u003e50 mL/min). We evaluated the tolerability and grade 2 or severer adverse events of capecitabine treatment. One hundred four patients had normal and 10 had impaired renal function (CrCL \u003c50 mL/min). Among the 104 patients with normal renal function, 23 (22.1%) had pseudo-normal renal function. Seventeen patients completed the eight cycles of Cape-Ox therapy without treatment delay or dose reduction, and all of them had truly normal renal function. The patients with pseudo-normal renal function were more likely to have grade 2 or severer thrombocytopenia than those with truly normal renal function. We should recognize correctly the clinical impact of standardized creatinine in the treatment of borderline renal function with Cape-Ox regimen in patients.", "subitem_description_language": "en", "subitem_description_type": "Abstract"}]}, "item_9_identifier_registration": {"attribute_name": "ID登録", "attribute_value_mlt": [{"subitem_identifier_reg_text": "10.18999/nagjms.84.3.547", "subitem_identifier_reg_type": "JaLC"}]}, "item_9_publisher_32": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Nagoya University Graduate School of Medicine, School of Medicine", "subitem_publisher_language": "en"}]}, "item_9_relation_43": {"attribute_name": "関連情報", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/843.html", "subitem_relation_type_select": "URI"}}]}, "item_9_rights_12": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International", "subitem_rights_language": "en", "subitem_rights_resource": "http://creativecommons.org/licenses/by-nc-nd/4.0/"}]}, "item_9_source_id_7": {"attribute_name": "収録物識別子", "attribute_value_mlt": [{"subitem_source_identifier": "0027-7622", "subitem_source_identifier_type": "PISSN"}, {"subitem_source_identifier": "2186-3326", "subitem_source_identifier_type": "EISSN"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "open access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_abf2"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Ito, Ayaka", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Ichikawa, Kazuya", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Miyazaki, Masayuki", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Sagara, Atsunobu", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Motegi, Toshiki", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Ando, Yuichi", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Senzaki, Koji", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Nagai, Taku", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Yamada, Kiyofumi", "creatorNameLang": "en"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_access", "date": [{"dateType": "Available", "dateValue": "2022-09-06"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "07_Ito.pdf", "filesize": [{"value": "437 KB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_5", "mimetype": "application/pdf", "size": 437000.0, "url": {"objectType": "fulltext", "url": "https://nagoya.repo.nii.ac.jp/record/2003747/files/07_Ito.pdf"}, "version_id": "01a1855d-7178-4291-9da8-2471963cf704"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "capecitabine", "subitem_subject_scheme": "Other"}, {"subitem_subject": "creatinine clearance", "subitem_subject_scheme": "Other"}, {"subitem_subject": "renal function", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Clinical impact of standardized creatinine on dose adjustment of capecitabine", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Clinical impact of standardized creatinine on dose adjustment of capecitabine", "subitem_title_language": "en"}]}, "item_type_id": "40001", "owner": "1", "path": ["1662337921058"], "permalink_uri": "https://doi.org/10.18999/nagjms.84.3.547", "pubdate": {"attribute_name": "PubDate", "attribute_value": "2022-09-05"}, "publish_date": "2022-09-05", "publish_status": "0", "recid": "2003747", "relation": {}, "relation_version_is_last": true, "title": ["Clinical impact of standardized creatinine on dose adjustment of capecitabine"], "weko_shared_id": -1}
  1. C100 医学部/医学系研究科
  2. C100b 紀要
  3. Nagoya journal of medical science
  4. 84(3)

Clinical impact of standardized creatinine on dose adjustment of capecitabine

https://doi.org/10.18999/nagjms.84.3.547
https://doi.org/10.18999/nagjms.84.3.547
da322ec3-28fb-4871-9996-c5d2fa4a435f
名前 / ファイル ライセンス アクション
07_Ito.pdf 07_Ito.pdf (437 KB)
license.icon
Item type itemtype_ver1(1)
公開日 2022-09-05
タイトル
タイトル Clinical impact of standardized creatinine on dose adjustment of capecitabine
言語 en
著者 Ito, Ayaka

× Ito, Ayaka

en Ito, Ayaka

Search repository
Ichikawa, Kazuya

× Ichikawa, Kazuya

en Ichikawa, Kazuya

Search repository
Miyazaki, Masayuki

× Miyazaki, Masayuki

en Miyazaki, Masayuki

Search repository
Sagara, Atsunobu

× Sagara, Atsunobu

en Sagara, Atsunobu

Search repository
Motegi, Toshiki

× Motegi, Toshiki

en Motegi, Toshiki

Search repository
Ando, Yuichi

× Ando, Yuichi

en Ando, Yuichi

Search repository
Senzaki, Koji

× Senzaki, Koji

en Senzaki, Koji

Search repository
Nagai, Taku

× Nagai, Taku

en Nagai, Taku

Search repository
Yamada, Kiyofumi

× Yamada, Kiyofumi

en Yamada, Kiyofumi

Search repository
アクセス権
アクセス権 open access
アクセス権URI http://purl.org/coar/access_right/c_abf2
権利
言語 en
権利情報Resource http://creativecommons.org/licenses/by-nc-nd/4.0/
権利情報 Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
キーワード
主題Scheme Other
主題 capecitabine
キーワード
主題Scheme Other
主題 creatinine clearance
キーワード
主題Scheme Other
主題 renal function
内容記述
内容記述 Although the Cockcroft-Gault equation is still used for the dose adjustment of many drugs that have been approved prior to creatinine standardization, the clinical impact of standardized creatinine in the dose adjustment of capecitabine is poorly understood. We focused on patients with borderline renal function and evaluated the tolerability and safety of capecitabine in patients who received capecitabine plus oxaliplatin (Cape-Ox). We retrospectively identified patients with resected colorectal cancer who had received adjuvant therapy with Cape-Ox regimen. Creatinine clearance (CrCL) was calculated by the Cockcroft–Gault equation with standardized creatinine measured using enzymatic methods, and adjusted CrCL was estimated by adding 0.2 (mg/dL) to the serum creatinine in the equation. We defined patients with “pseudo-normal” renal function as those who had an adjusted CrCL of ≤50 mL/min in patients with normal renal function (CrCL >50 mL/min). We evaluated the tolerability and grade 2 or severer adverse events of capecitabine treatment. One hundred four patients had normal and 10 had impaired renal function (CrCL <50 mL/min). Among the 104 patients with normal renal function, 23 (22.1%) had pseudo-normal renal function. Seventeen patients completed the eight cycles of Cape-Ox therapy without treatment delay or dose reduction, and all of them had truly normal renal function. The patients with pseudo-normal renal function were more likely to have grade 2 or severer thrombocytopenia than those with truly normal renal function. We should recognize correctly the clinical impact of standardized creatinine in the treatment of borderline renal function with Cape-Ox regimen in patients.
言語 en
内容記述タイプ Abstract
出版者
言語 en
出版者 Nagoya University Graduate School of Medicine, School of Medicine
言語
言語 eng
資源タイプ
資源タイプresource http://purl.org/coar/resource_type/c_6501
タイプ departmental bulletin paper
出版タイプ
出版タイプ VoR
出版タイプResource http://purl.org/coar/version/c_970fb48d4fbd8a85
ID登録
ID登録 10.18999/nagjms.84.3.547
ID登録タイプ JaLC
関連情報
関連タイプ isVersionOf
識別子タイプ URI
関連識別子 https://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/843.html
収録物識別子
収録物識別子タイプ PISSN
収録物識別子 0027-7622
収録物識別子
収録物識別子タイプ EISSN
収録物識別子 2186-3326
書誌情報 en : Nagoya Journal of Medical Science

巻 84, 号 3, p. 547-553, 発行日 2022-08
戻る
0
views
See details
Views

Versions

Ver.1 2022-09-05 02:39:44.048718
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3